US FDA invites companies to participate in drug names pilot
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is inviting pharmaceutical and biotech companies to participate in its much-anticipated pilot programme on the evaluation of drug proprietary names. Under the pilot, companies will be able to check in advance whether their proposed invented trade names are likely to be acceptable to the FDA1,2.
You may also be interested in...
India Proposes Tiered Approach To Oversee Genome Editing
India has proposed three categories for grouping genetically edited organisms based on the complexity of modifications.
UK's MHRA Looks Beyond Brexit Transition Period
Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.
UK MHRA Looks Beyond Brexit Transition
Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: